3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
20
Sarcoma
8
Breast Neoplasms
5
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Carcinoma, Squamous Cell
3
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Carcinoma, Basal Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Sarcoma, Kaposi
1
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Peritoneal Neoplasms
1
Paget Disease, Extramammary
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma
1
Muir-Torre Syndrome
1
Microcystic adnexal carcinoma
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Interventions
Doxorubicin
10
Zidovudine
9
Vincristine
7
Bleomycin
7
Nivolumab
6
Liposomes
5
Interferon alpha-2
5
Etoposide
5
tecogalan
4
pembrolizumab
4
liposomal doxorubicin
4
Valganciclovir
4
Specimen Handling
4
Semaxinib
4
Paclitaxel
4
Nelfinavir
4
Magnetic Resonance Spectroscopy
4
pomalidomide
3
Ritonavir
3
Filgrastim
3
Biopsy
3
Bevacizumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
2
sargramostim
2
interferon alfa-n1
2
Propranolol
2
Indinavir
2
Docetaxel
2
Didanosine
2
Daunorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma, Kaposi
×
talimogene laherparepvec
×
Clear all
NCT04065152
2022-06-10
KAPVEC
Assistance Publique - Hôpitaux de Paris
Phase 2
Unknown
20 enrolled